RT Journal Article
T1 Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
A1 Gutierrez, Antonio
A1 Bento, Leyre
A1 Diaz-Lopez, Antonio
A1 Barranco, Gilberto
A1 Garcia-Recio, Marta
A1 Lopez-Guillermo, Armando
A1 Dlouhy, Ivan
A1 Rovira, Jordina
A1 Rodriguez, Mario
A1 Sanchez Pina, Jose María
A1 Baile, Monica
A1 Martín, Alejandro
A1 Novelli, Silvana
A1 Sancho, Juan-Manuel
A1 García, Olga
A1 Salar, Antonio
A1 Bastos-Oreiro, Mariana
A1 Rodriguez-Salazar, Mª José
A1 Fernandez, Ruben
A1 de la Cruz, Fatima
A1 Queizan, Jose Antonio
A1 González de Villambrosia, Sonia
A1 Cordoba, Raul
A1 López, Andres
A1 Luzardo, Hugo
A1 García, Daniel
A1 Sastre-Serra, Jordi
A1 Garcia, Juan Fernando
A1 Montalban, Carlos
A1 Cabanillas, Fernando
A1 Rodríguez, Jose
K1 diffuse large B-cell lymphoma
K1 international prognostic index
K1 prognosis
K1 score
K1 tumor score
AB Diffuse large B-cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%-40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot identify a very high-risk (HR) subset. The MD Anderson Cancer Center reported a score in the prerituximab era exclusively considering tumor-related variables: Tumor Score (TS). We aim to validate TS in the rituximab era and to analyze its current potential role. From GELTAMO DLBCL registry, we selected those patients homogeneously treated with R-CHOP (n = 1327). Five-years PFS and OS were 62% and 74%. All variables retained an independent prognostic role in the revised TS (R-TS), identifying four different risk groups, with 5-years PFS of 86%, 71%, 50%, and very HR (28%). With a further categorization of three variables of the original TS (Ann Arbor Stage, LDH and B2M), we generated a new index that allowed an improvement in HR assessment. (a) All variables of the original TS retain an independent prognostic role, and R-TS remains predictive in the rituximab era; (b) R-TS and additional categorization of LDH, B2M, and AA stage (enhanced TS) increased the ability to identify HR subsets.
YR 2020
FD 2020-02-18
LK http://hdl.handle.net/10668/14791
UL http://hdl.handle.net/10668/14791
LA en
DS RISalud
RD Apr 11, 2025